Concerns rise among Korean drug makers

The domestic pharmaceutical sector is expected to face an inevitable blow under the government’s scheme to cut drug prices as part of its efforts to stamp out illegal rebate provisions.

Prospects have been grim for Korean firms, as they are getting pressed by multinationals' increasing market presence and the government's pressure to lower drug costs. Generic drugs have long been the competi...